The Board of Directors have at their meeting held today, 14-08-2025, approved to acquire land, building, plant and machinery located at plot no. D-22, IDA-Medchal, Medchal Mandal, Malkajigiri ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Sudarshan Pharma Industries approved the acquisition of land, building and plant & machinery spread over 1,563.15 sq. meters at Plot D-22, IDA-Medchal, Telangana, for a total cash consideration of Rs. 25.50 Crores from Srigen Lifesciences Private Limited. The acquired facility is an API manufacturing plant with 80 Kilolitres of reactor capacity and has developed around 50 potential API key starting materials, including products like Ropivacaine, Bupivacaine, Sitagliptin and Apixaban. The company clarified the transaction is not a related party transaction. The acquisition is expected to be completed by 31st December 2025 and is aimed at expanding the company's production capabilities in the pharmaceutical and chemical segment.
This is a brownfield expansion that should boost Sudarshan Pharma's manufacturing capacity and product portfolio in APIs, potentially supporting future revenue growth. However, the Rs. 25.50 Crores cash outflow will need to be assessed against the company's net worth and cash position to gauge its financial impact.